Vectorite Biomedical Inc. (TPEX:4170)

Market Cap	612.80M +0.4%
Revenue (ttm)	67.90M +27.0%
Net Income	-23.19M
EPS	-0.53
Shares Out	43.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	92,744
Average Volume	45,051
Open	13.75
Previous Close	14.10
Day's Range	13.30 - 14.05
52-Week Range	10.40 - 18.15
Beta	0.35
RSI	50.65
Earnings Date	Apr 27, 2026

About Vectorite Biomedical

Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It is involved in cell preparation product manufacturing; and collection and storage of immune cells. The company’s products are used in the field of infectious diseases and inflammation, cancer, oncology. Vectorite Biomedical Inc. was incorporated in 2004 and is based in New Taipei City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4170

Financial Performance

In 2024, Vectorite Biomedical's revenue was 57.77 million, an increase of 3.43% compared to the previous year's 55.85 million. Losses were -40.05 million, 506.8% more than in 2023.